Improved Quality and Diagnostic Confidence Achieved by Use of Dose-Reduced Gadolinium Blood-Pool Agents for Time-Resolved Intracranial MR Angiography

REFERENCES

1. 1.↵
   1. Korosec FR,
   2. Frayne R,
   3. Grist TM,
   4. et al

   . Time-resolved contrast-enhanced 3D MR angiography. Magn Reson Med 1996;36:345–51

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Lim RP,
   2. Shapiro M,
   3. Wang EY,
   4. et al

   . 3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced bolus-chase MRA and 3D time-of-flight MRA. AJNR Am J Neuroradiol 2008;29:1847–54

   Abstract/FREE Full Text
3. 3.↵
   1. Willinek WA,
   2. Hadizadeh DR,
   3. von Falkenhausen M,
   4. et al

   . 4D time-resolved MR angiography with keyhole (4D-TRAK): more than 60 times accelerated MRA using a combination of CENTRA, keyhole, and SENSE at 3.0T. J Magn Reson Imaging 2008;27:1455–60

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Maki JH,
   2. Wang M,
   3. Wilson GJ,
   4. et al

   . Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents. J Magn Reson Imaging 2009;30:1085–92

   CrossRefPubMed
5. 5.↵
   1. Lin W,
   2. Haacke EM,
   3. Smith AS,
   4. et al

   . Gadolinium-enhanced high-resolution MR angiography with adaptive vessel tracking: preliminary results in the intracranial circulation. J Magn Reson Imaging 1992;2:277–84

   CrossRefPubMed
6. 6.↵
   1. Collidge TA,
   2. Thomson PC,
   3. Mark PB,
   4. et al

   . Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168–75

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Caravan P,
   2. Cloutier NJ,
   3. Greenfield MT,
   4. et al

   . The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 2002;124:3152–62

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Muller RN,
   2. Gillis P,
   3. Moiny F,
   4. et al

   . Transverse relaxivity of particulate MRI contrast media: from theories to experiments. Magn Reson Med 1991;22:178–82

   CrossRefPubMed
9. 9.↵
   1. Rohrer M,
   2. Bauer H,
   3. Mintorovitch J,
   4. et al

   . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Hartmann M,
    2. Wiethoff AJ,
    3. Hentrich HR,
    4. et al

    . Initial imaging recommendations for Vasovist angiography. Eur Radiol 2006;16(Suppl 2):B15–23

    CrossRefPubMed
11. 11.↵
    1. Lauffer RB,
    2. Parmelee DJ,
    3. Dunham SU,
    4. et al

    . MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998;207:529–38

    PubMedWeb of Science
12. 12.↵
    1. Niendorf HP,
    2. Felix R,
    3. Laniado M,
    4. et al

    . Gadolinium-DTPA: a new contrast agent for magnetic resonance imaging. Radiat Med 1985;3:7–12

    PubMed
13. 13.↵
    1. Frydrychowicz A,
    2. Russe MF,
    3. Bock J,
    4. et al

    . Comparison of gadofosveset trisodium and gadobenate dimeglumine during time-resolved thoracic MR angiography at 3T. Acad Radiol 2010;17:1394–400

    CrossRefPubMed
14. 14.↵
    1. Klessen C,
    2. Hein PA,
    3. Huppertz A,
    4. et al

    . First-pass whole-body magnetic resonance angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: comparison to gadopentetate dimeglumine. Invest Radiol 2007;42:659–64

    CrossRefPubMed
15. 15.↵
    1. Naehle CP,
    2. Muller A,
    3. Willinek WA,
    4. et al

    . First-pass and steady-state magnetic resonance angiography of the thoracic vasculature using gadofosveset trisodium. J Magn Reson Imaging 2009;30:809–16

    CrossRefPubMed
16. 16.↵
    1. Nielsen YW,
    2. Eiberg JP,
    3. Logager VB,
    4. et al

    . Whole-body MR angiography with body coil acquisition at 3 T in patients with peripheral arterial disease using the contrast agent gadofosveset trisodium. Acad Radiol 2009;16:654–61

    CrossRefPubMed
17. 17.↵
    1. Nissen JC,
    2. Attenberger UI,
    3. Fink C,
    4. et al

    . Thoracic and abdominal MRA with gadofosveset: influence of injection rate on vessel signal and image quality. Eur Radiol 2009;19:1932–38

    CrossRefPubMed
18. 18.↵
    1. Bleicher AG,
    2. Kanal E

    . A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR Am J Neuroradiol 2008;29:668–73

    Abstract/FREE Full Text
19. 19.↵
    1. Pintaske J,
    2. Martirosian P,
    3. Graf H,
    4. et al

    . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21

    CrossRefPubMed
20. 20.↵
    1. Dössel O,
    2. Schlegel W

    1. Kiefer C,
    2. El-Koussy M,
    3. Schroth G,
    4. et al

    . Theoretical and clinical aspects of TWIST based 4D time-resolved MR angiography. In: Dössel O, Schlegel W, eds. World Congress on Medical Physics and Biomedical Engineering, September 7–12, 2009, Munich, Germany. Berlin/Heidelberg: Springer-Verlag; 2009:466–69
21. 21.↵
    1. Rapp JH,
    2. Wolff SD,
    3. Quinn SF,
    4. et al

    . Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography: multicenter comparative phase III study. Radiology 2005;236:71–78

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Reeder SB,
    2. Wintersperger BJ,
    3. Dietrich O,
    4. et al

    . Practical approaches to the evaluation of signal-to-noise ratio performance with parallel imaging: application with cardiac imaging and a 32-channel cardiac coil. Magn Reson Med 2005;54:748–54

    CrossRefPubMed
23. 23.↵
    1. Bluemke DA,
    2. Stillman AE,
    3. Bis KG,
    4. et al

    . Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology 2001;219:114–22

    CrossRefPubMed
24. 24.↵
    1. Hadizadeh DR,
    2. Gieseke J,
    3. Lohmaier SH,
    4. et al

    . Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. Radiology 2008;249:701–11

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Michaely HJ,
    2. Attenberger UI,
    3. Dietrich O,
    4. et al

    . Feasibility of gadofosveset-enhanced steady-state magnetic resonance angiography of the peripheral vessels at 3 Tesla with Dixon fat saturation. Invest Radiol 2008;43:635–41

    CrossRefPubMed
26. 26.↵
    1. Michaely HJ,
    2. Kramer H,
    3. Dietrich O,
    4. et al

    . Intraindividual comparison of high-spatial-resolution abdominal MR angiography at 1.5 T and 3.0 T: initial experience. Radiology 2007;244:907–13

    CrossRefPubMedWeb of Science